Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTC-TDF in Early Alzheimer's Disease
NCT07795307Phase 1Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing FTC and TDF combination tablet with Placebo (2 arms). Primary endpoint: Safety and tolerability at 28 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
emtricitabinetenofovir disoproxil fumarate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07795307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795307.